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Diagnosis of poisoning by organophosphates (OPs) and carbamates is made on the
basis of clinical symptoms and laboratory tests for plasma butyrylcholinesterase (BuChE:
EC 3.1.1.8, acylcholine acylhydrolase, plasma cholinesterase) and red blood cells acetyl-
cholinesterase (AChE: EC 3.1.1.7) catalytic activity. Butyrylcholinesterase is synthesized
in the liver and is released into plasma immediately upon synthesis. Some authors pro-
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The paper describes the effect of glucocorticoid dexame-
thasone (DM) given intraperitoneally on the catalytic acti-
vity of butyrylcholinesterase (BuChE) measured in plasma,
liver and white adipose tissue of rats of both sexes. Effects
of DM on the concentration of plasma lipids and lipopro-
teins were also tested. Rats were given multiple (2 and 4)
pharmacological doses (0.4 and 3.0 mg kg–1 body mass)
of DM. All animals were sacrificed 48 hours after the last
dose. Administration of DM significantly decreased the
catalytic activity of BuChE in plasma and liver of all tre-
ated groups regardless of sex. BuChE catalytic activity in
white adipose tissue differed depending on the dose and
frequency of administration. In contrast to liver where
both doses caused significant BuChE inhibition, the lower
DM dose did not inhibit BuChE activity in adipose tis-
sue, and the inhibition achieved by the higher dose was
not as strong as in liver. This result corroborates an earlier
hypothesis that BuChE is also synthesized in the adipose
tissue. DM significantly increased plasma concentrations
of triglycerides, total cholesterol and high-density lipo-
protein (HDL) cholesterol and decreased the low-density
lipoprotein (LDL) cholesterol concentration. Neither posi-
tive correlation between BuChE and triglycerides nor ne-
gative correlation between BuChE and HDL was found.
Changes in lipid profile during DM treatment were not
sex- and time-dependent.
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pose that BuChE synthesis is not limited to the liver alone (1, 2). This enzyme has been
found in the small intestine, smooth muscle, heart, adipose tissue, and in white matter
of the brain, where it plays a minor role in regulating brain acetylcholine levels. So far,
BuChE has no known biological substrate in the mammals, but it hydrolyzes a variety of
choline esters, including butyrylcholine, butyrylthiocholine and propionylthiocholine
(3). BuChE is clinically important because it hydrolyzes the short-acting muscle relaxant
succinylcholine as well as ester-type local anaesthetics (4). Although the physiological
function of BuChE is not known, it has been suggested that it might be a precursor of
AChE in the nervous system, and that it might contribute to the integrity of the myelin
sheath of the central axons (5). According to recent investigations, BuChE activity pro-
gressively increases in patients with Alzheimer’s disease and both BuChE and AChE
seem to be involved in the aetiology and progression of this disease (6). Many data show
that BuChE also plays a role in lipid and lipoprotein metabolism (1, 2, 7, 8).
For practical reasons it is important to determine whether a decrease in BuChE ac-
tivity is caused by a qualitative change of the enzyme (genetic variant) or by its quanti-
tative reduction. In the case of qualitative changes, the decrease in BuChE activity is in-
herited (a rare genetic variant of atypical or dibucaine-resistant enzyme) and constant.
In such persons, the hydrolysis and inactivation of the muscle-relaxant drug suxametho-
nium is of long duration (9). The frequency of quantitative reduction is significantly
higher and it could be a consequence of decreased enzyme synthesis due to cancer, mal-
nutrition, liver or renal diseases (10, 11). It is also known that acute or chronic treatment
with steroid hormones (glucocorticoids and estrogens) inhibits the activity of BuChE in
plasma and liver (12, 13), but this effect does not occur in vitro. Therefore, it has been
suggested that glucocorticoids reversibly depress the synthesis of BuChE in the liver
(13). On the other hand, many drugs, such as neostigmine, pyridostigmine or propra-
nolol, directly inhibit the active centre and peripheral anionic site of the enzyme (7, 14).
Our recent experiments with a single-non-lethal dose of cycloheximide (CHM), a
strong inhibitor of protein synthesis in mammals, have shown that the catalytic activity
of BuChE in the plasma of rats of both sexes remained unchanged for several days after
CHM administration (15). At the same time, the catalytic activity of BuChE in the liver
and white adipose tissue was significantly inhibited (15). The reason for the maintained
BuChE catalytic activity in plasma could be a relatively long biological half-life of this
enzyme in rat plasma (9–11 days). Significant differences in the dynamics of the inhibi-
tion of BuChE activity between the liver and white adipose tissue obtained in these ex-
periments support the hypothesis that BuChE is also synthesized in adipose tissue.
The aim of this study was to determine the time-course of dexamethasone (DM)-re-
lated BuChE inhibition in the adipose tissue, liver, and plasma of rats of both sexes, be-
cause of the significant effect of sex hormones on BuChE catalytic activity. Based on the
relationship between BuChE and plasma lipids, we wanted to find whether there was a
positive correlation between BuChE and triglycerides and a negative correlation be-
tween BuChE and HDL during DM therapy. The effect of DM on plasma lipids concen-
tration was measured and compared between rats of both sexes.
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EXPERIMENTAL
Chemicals
Dexamethasone sodium phosphate (9-fluoro 16-methylprednisolone) was obtai-
ned from Krka (Slovenia).
Treatment of animals
Male and female adult Wistar rats (240–280 g body mass) were fed a standard diet
for laboratory rodents (Sljeme, Croatia). Animals had free access to water and were kept
in macrolone cages under controlled conditions (room temperature 21 °C, light and dark
cycles exchanging every 12 hours).
The animals (32 males and 32 females) were randomly divided in eight control (n = 3)
and eight test groups (n = 5) receiving DM intraperitoneally at 48-hour intervals. Four
test groups (2 male and 2 female) received 0.4 mg DM kg–1 body mass (b.m.). Of these
four groups, one male and one female group received two doses, while the others re-
ceived four doses. The same scheme was used for the administration of higher DM doses
(3.0 mg kg–1 b.m.). The controls were given saline using the same experimental design.
All treated animals were sacrificed with coal gas 48 hours after the last dose.
In order to achieve continuous pharmacodynamic effects of DM without serious si-
de effects, and knowing that the biological half-life of DM is 56 hours, animals were trea-
ted every other day.
Blood samples were obtained directly from the heart, and adipose tissue was iso-
lated from the epididymal (males) or parametrial (females) fat depot. The liver tissue
was rinsed with saline. Plasma and tissue samples were stored and frozen immediately
after sampling at –20 °C until further processing. Tissue samples were homogenized
(200 mg tissue mL–1 saline) and supernatant was obtained by centrifuging for 15 min at
2800  g.
This study was performed with the approval of the Ethical Committee of the Insti-
tute for Medical Research and Occupational Health in Zagreb, Croatia.
BuChE assay
The BuChE activity in plasma and tissues (liver and white adipose tissue) was de-
termined by spectrophotometry using butyrylthiocholine (0.9 mmol L–1) (Sigma Chem
Co., USA) as a substrate (16). Since the liver tissue contains BuChE and AChE, the BuChE
assay was carried out with and without the specific BuChE inhibitor ethopropazine hy-
drochloride in the final concentration of 1.7 mmol L–1 (Sigma Chem Co.). BuChE activity
was calculated indirectly as the difference of the two measurements. The enzyme activ-
ity is expressed as mol of substrate hydrolyzed per min per mL of plasma, i.e., mol of
substrate hydrolyzed per min per g of fresh tissue. Since there was no statistical evidence
difference in BuChE activity between control groups of the same sex either in plasma or
in tissues, the mean BuChE activity in males and separately in females was taken as the
control value. Relative changes in the enzyme activity in the treated animals are presented
as the percentage of the control group activity.
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Lipids and lipoproteins
Total cholesterol in plasma was determined using a cholesterol enzymatic colorime-
tric test (»Herbos« Dijagnostika, Croatia) (17, 18) while triglycerides were determined
using a triglyceride enzymatic colorimetric test – GPO-PAP method (»Olympus Diag-
nostica« GmbH, Germany) (19, 20). HDL cholesterol levels were determined using the
method of Burstein et al. (21). Friedewald's formula was used to calculate LDL choles-
terol levels from total cholesterol, triglycerides and HDL cholesterol (22). Concentrations
of lipids and lipoproteins were measured in duplicate, and expressed as mmol L–1 of
plasma. Relative changes in lipid and lipoprotein concentrations in treated animals are
shown as the percentage of all rats of the respective control group. Since there was no
significant difference in triglycerides, total cholesterol, HDL cholesterol, and LDL cho-
lesterol concentrations between the control groups, the mean concentrations of respec-
tive parameters of all rats were taken as control values.
Statistical analysis
Data are shown as mean  standard deviation. The mean and medians were calcu-
lated using the software package Statistics® for Windows version 5.0 A. Statistical signif-
icance was determined by the parametric t-test and non-parametric Kolmogorov-Smir-
nov two-sample test, where appropriate. The differences discussed in this paper were
considered significant at the p < 0.05 level of significance.
RESULTS AND DISCUSION
In this study, the inhibitory effect of DM on BuChE catalytic activity in plasma, liver
and white adipose tissue was demonstrated in most of our experimental groups when
compared with the controls (results are summarized in Table I).
A significant decrease (p < 0.05) in BuChE catalytic activity (approximately 20–80%)
was found in the liver of rats of both sexes, which was dose- but not time-dependent. It
is known that glucocorticoids interact with specific receptor proteins in the target tissue,
thus regulating (reversible increase or decrease) the expression of corticosteroid-respon-
sive genes that affect protein synthesis (23). Therefore, the decreased catalytic activity of
BuChE in the liver may be attributed to DM inhibition of its synthesis. It is also known
that the hepatic glucocorticoid receptor-binding capacity decreases significantly in rats
after the scalding stress, mainly as a result of the increased concentration of serum cor-
ticosterone (24). Both doses of glucocorticoids applied in our experiments were pharma-
cologically high, and their plasma concentrations were high due to the long half-life of
DM. Dose and dosing period increments did not further increase the inhibition of BuChE
activity in rat liver, which suggests a reduced binding capacity of glucocorticoid recep-
tors. Decrease in BuChE catalytic activity in rats receiving the higher dose was greater
(65–80%) in the liver than in plasma (20–45%). The presence of BuChE that was synthe-
sized and released into plasma before the DM administration and its relatively long-
-half-life in plasma (9–11 days) are probably the main reasons why the activity of BuChE
was greater in plasma than in liver. A similar difference between the BuChE activity in the
liver and plasma was reported by Verjee et al. (12).
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The effect of DM on BuChE activity in the adipose tissue showed quite a different
pattern. Two low doses of DM (0.4 mg kg–1) did not change BuChE activity in the adi-
pose tissue of rats of either sex, but four administrations of the same dose caused an un-
expected significant (p < 0.05) increase in BuChE activity (about 35–45%) when compared
to the controls. Both two and four administrations of high doses of DM (3.0 mg kg–1)
produced a similar significant (p < 0.05) decrease in BuChE activity (about 50%) in the
white adipose tissue of rats of both sexes. This different pattern of BuChE activity in the
adipose tissue and in the liver after a low DM dose administration could indicate that
the binding capacity of glucocorticoid receptors and their sensitivity to DM in the adi-
pose tissue differ from that in the liver. Our results indicate that the BuChE is also syn-
thesized in the adipose tissue. The possibility that adipose tissue is a place of BuChE
synthesis is supported by the results of Ballantyne (25) and Salvador and Kuntzman
(26), who histochemically demonstrated the presence of BuChE in adipocytes.
According to our results, the administration of two different doses of DM to male
and female rats significantly increases total cholesterol, HDL cholesterol and triglycer-
ides in plasma (Table II). Plasma LDL cholesterol was lower than in the control groups
treated with saline. These changes were not dose-dependent. Similar effects of DM on
plasma lipids were reported by other authors (27, 28). It is not known why glucocor-
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a Mean ± SD.
b Comparison with controls: c t-test p < 0.05, d t-test p < 0.01, e t-test p < 0.001, f Kolmogorov-Smirnov test
p < 0.05, g Kolmogorov-Smirnov test p < 0.01, h Kolmogorov-Smirnov test p < 0.001.
ticoids have different effects on the plasma lipid profile. However, it is known that glu-
cocorticoids may act through several mechanisms on different levels of the lipoprotein
metabolism. Namely, corticosteroids may affect lipoprotein synthesis and increase the
very-low-density lipoprotein (VLDL cholesterol) secretion in rats. On the other hand,
they affect the lipoprotein catabolism. It has been shown that corticosteroids decrease li-
poprotein lipase activity in the adipose tissue and therefore impair the plasma trigly-
ceride metabolism. The mechanisms causing changes in HDL cholesterol are not well
known either (27, 28). We have to stress that, according to our own results, changes in
the lipid profile during DM treatment were not sex- and time-dependent.
The mean BuChE activity in plasma, liver and white adipose tissue was higher (1.5–
3 times) in female than in male control rats. This sex-related difference is in agreement
with the results published by other authors (29). They have noticed a negative modula-
tory effect of testosterone and a positive modulatory effect of estrogens on serum BuChE
synthesis in the rat liver. The mode of action of both sex hormones on the enzyme syn-
thesis in hepatocytes is not direct, but includes the hypothalamic-hypophyseal axis (30).
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Our results indicate that the interaction between glucocorticoids and BuChE can be
of clinical significance. Glucocorticoids are often used in the therapy of different disea-
ses, and may cause a drop in BuChE activity. Therefore, this therapy could prolong hy-
drolysis of succinylcholine during anaesthesia.
CONCLUSIONS
The decrease in the liver BuChE activity was similar in rats of both sexes after re-
ceiving either low or high pharmacological doses of DM. Furthermore, the dynamics of
increase after a low dose and decrease after a high dose of DM was very similar in the
adipose tissue of rats of either sex. It might be assumed that these changes in BuChE ac-
tivity in the liver and adipose tissue are primarily a consequence of DM effects on the
glucocorticoid receptors of target cells. We are also inclined to believe that DM had a
synergistic effect with testosterone and an opposite effect with estrogens on BuChE syn-
thesis in the liver of treated male and female rats. Dose-related differences in the effects
of DM on BuChE activity in the white adipose tissue call for further investigation in this
area.
There was neither a positive correlation between BuChE and triglycerides nor a ne-
gative correlation between BuChE and HDL. Changes in the lipid profile during DM tre-
atment were not sex- and time-dependent.
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S A @ E T A K
U~inak deksametazona na aktivnost butirilkolinesteraze i lipide plazme u {takora
ANA LUCI] VRDOLJAK, VLASTA BRADAMANTE, BO@ICA RADI], MAJA PERAICA, RADOVAN FUCHS i @ELJKO REINER
U radu su opisani u~inci glukokortikoida deksametazona (DM) na kataliti~ku ak-
tivnost butirilkolinesteraze (BuChE) u plazmi, jetri i bijelom masnom tkivu {takora oba
spola. Ispitan je i u~inak DM na koncentracije plazmatskih lipida i lipoproteina. [takori
su tretirani vi{ekratno (2 i 4 puta) farmakolo{kim dozama (0,4 i 3,0 mg kg–1 tjelesne mase)
DM koji je primijenjen intraperitonealno. @ivotinje su `rtvovane 48 sati nakon {to su
primile zadnju dozu. Utvr|eno je da DM zna~ajno sni`ava kataliti~ku aktivnost BuChE u
plazmi i jetri {takora oba spola. Rezultati kataliti~kih aktivnosti BuChE u bijelom mas-
nom tkivu bili su razli~iti ovisno o veli~ini doze i broju aplikacija. Za razliku od jetre,
gdje su obje doze izazvale zna~ajnu inhibiciju BuChE, u masnom tkivu ni`a doza nije
inhibirala aktivnost enzima, a inhibicija s vi{om dozom nije bila tako sna`na kao u jetri.
Rezultati govore u prilog hipotezi da se BuChE osim u jetri sintetizira i u masnom tkivu.
Tako|er je utvr|eno da DM zna~ajno pove}ava koncentraciju triglicerida, ukupnog ko-
lesterola i HDL-kolesterola, te smanjuje koncentraciju LDL-kolesterola u plazmi. Me|u-
tim, nije utvr|ena pozitivna korelacija izme|u BuChE i triglicerida, niti negativna kore-
lacija izme|u BuChE i HDL. Promjene koncentracija lipidnih frakcija tijekom primjene
DM nisu ovisile o spolu eksperimentalnih `ivotinja niti o trajanju pokusa.
Klju~ne rije~i: deksametazon, butirilkolinesteraza, jetra, bijelo masno tkivo, sinteza proteina, lipidi,
lipoproteini
Institut za medicinska istra`ivanja i medicinu rada, Zagreb
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